Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: A double-blinded clinical study

Kaoru Ogawa, Satoshi Takei, Yasuhiro Inoue, Jin Kanzaki

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective and Study Design: The authors conducted a prospective, randomized, double-blinded clinical trial for the purpose of elucidating the effects of prostaglandin E1 (PGE1) on idiopathic sudden sensorineural hearing loss. Setting and Patients: With the approval of the institute ethics committee, a total of 57 consecutive patients with diagnoses of idiopathic sudden sensorineural hearing loss were included in the study. The patients in the PGE1 group received continuous infusion containing 60 μg PGE1 and 100 mg hydrocortisone for 7 days, and the patients in the placebo group were treated with continuous infusion containing an inactive placebo and 100 mg hydrocortisone. Results: No significant differences were observed in the improvements of pure-tone average and subjective symptoms between the PGE1 and the placebo groups. However, the hearing improvement at high frequencies (4 kHz and 8 kHz) was significantly higher in the PGE1 group than in the placebo group, especially in the patients with severe tinnitus. Conclusions: These results failed to prove a beneficial effect of PGE1 in the treatment of idiopathic sudden sensorineural hearing loss. Further studies will be needed to clarify the pharmacologic actions of PGE1 in the cochlea.

Original languageEnglish
Pages (from-to)665-668
Number of pages4
JournalOtology and Neurotology
Volume23
Issue number5
Publication statusPublished - 2002 Sep
Externally publishedYes

Fingerprint

Sudden Hearing Loss
Sensorineural Hearing Loss
Alprostadil
Placebos
Hydrocortisone
Pharmacologic Actions
Ethics Committees
Tinnitus
Cochlea
Clinical Studies
Hearing
Clinical Trials

Keywords

  • Cytoprotection
  • Double-blinded clinical trial
  • Idiopathic sudden sensorineural hearing loss
  • Prostaglandin E1
  • Tinnitus

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Neuroscience(all)

Cite this

Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss : A double-blinded clinical study. / Ogawa, Kaoru; Takei, Satoshi; Inoue, Yasuhiro; Kanzaki, Jin.

In: Otology and Neurotology, Vol. 23, No. 5, 09.2002, p. 665-668.

Research output: Contribution to journalArticle

Ogawa, Kaoru ; Takei, Satoshi ; Inoue, Yasuhiro ; Kanzaki, Jin. / Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss : A double-blinded clinical study. In: Otology and Neurotology. 2002 ; Vol. 23, No. 5. pp. 665-668.
@article{7c901a9af0c54bcdb39cdc8c327e5b58,
title = "Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: A double-blinded clinical study",
abstract = "Objective and Study Design: The authors conducted a prospective, randomized, double-blinded clinical trial for the purpose of elucidating the effects of prostaglandin E1 (PGE1) on idiopathic sudden sensorineural hearing loss. Setting and Patients: With the approval of the institute ethics committee, a total of 57 consecutive patients with diagnoses of idiopathic sudden sensorineural hearing loss were included in the study. The patients in the PGE1 group received continuous infusion containing 60 μg PGE1 and 100 mg hydrocortisone for 7 days, and the patients in the placebo group were treated with continuous infusion containing an inactive placebo and 100 mg hydrocortisone. Results: No significant differences were observed in the improvements of pure-tone average and subjective symptoms between the PGE1 and the placebo groups. However, the hearing improvement at high frequencies (4 kHz and 8 kHz) was significantly higher in the PGE1 group than in the placebo group, especially in the patients with severe tinnitus. Conclusions: These results failed to prove a beneficial effect of PGE1 in the treatment of idiopathic sudden sensorineural hearing loss. Further studies will be needed to clarify the pharmacologic actions of PGE1 in the cochlea.",
keywords = "Cytoprotection, Double-blinded clinical trial, Idiopathic sudden sensorineural hearing loss, Prostaglandin E1, Tinnitus",
author = "Kaoru Ogawa and Satoshi Takei and Yasuhiro Inoue and Jin Kanzaki",
year = "2002",
month = "9",
language = "English",
volume = "23",
pages = "665--668",
journal = "Otology and Neurotology",
issn = "1531-7129",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss

T2 - A double-blinded clinical study

AU - Ogawa, Kaoru

AU - Takei, Satoshi

AU - Inoue, Yasuhiro

AU - Kanzaki, Jin

PY - 2002/9

Y1 - 2002/9

N2 - Objective and Study Design: The authors conducted a prospective, randomized, double-blinded clinical trial for the purpose of elucidating the effects of prostaglandin E1 (PGE1) on idiopathic sudden sensorineural hearing loss. Setting and Patients: With the approval of the institute ethics committee, a total of 57 consecutive patients with diagnoses of idiopathic sudden sensorineural hearing loss were included in the study. The patients in the PGE1 group received continuous infusion containing 60 μg PGE1 and 100 mg hydrocortisone for 7 days, and the patients in the placebo group were treated with continuous infusion containing an inactive placebo and 100 mg hydrocortisone. Results: No significant differences were observed in the improvements of pure-tone average and subjective symptoms between the PGE1 and the placebo groups. However, the hearing improvement at high frequencies (4 kHz and 8 kHz) was significantly higher in the PGE1 group than in the placebo group, especially in the patients with severe tinnitus. Conclusions: These results failed to prove a beneficial effect of PGE1 in the treatment of idiopathic sudden sensorineural hearing loss. Further studies will be needed to clarify the pharmacologic actions of PGE1 in the cochlea.

AB - Objective and Study Design: The authors conducted a prospective, randomized, double-blinded clinical trial for the purpose of elucidating the effects of prostaglandin E1 (PGE1) on idiopathic sudden sensorineural hearing loss. Setting and Patients: With the approval of the institute ethics committee, a total of 57 consecutive patients with diagnoses of idiopathic sudden sensorineural hearing loss were included in the study. The patients in the PGE1 group received continuous infusion containing 60 μg PGE1 and 100 mg hydrocortisone for 7 days, and the patients in the placebo group were treated with continuous infusion containing an inactive placebo and 100 mg hydrocortisone. Results: No significant differences were observed in the improvements of pure-tone average and subjective symptoms between the PGE1 and the placebo groups. However, the hearing improvement at high frequencies (4 kHz and 8 kHz) was significantly higher in the PGE1 group than in the placebo group, especially in the patients with severe tinnitus. Conclusions: These results failed to prove a beneficial effect of PGE1 in the treatment of idiopathic sudden sensorineural hearing loss. Further studies will be needed to clarify the pharmacologic actions of PGE1 in the cochlea.

KW - Cytoprotection

KW - Double-blinded clinical trial

KW - Idiopathic sudden sensorineural hearing loss

KW - Prostaglandin E1

KW - Tinnitus

UR - http://www.scopus.com/inward/record.url?scp=0036736129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036736129&partnerID=8YFLogxK

M3 - Article

C2 - 12218617

AN - SCOPUS:0036736129

VL - 23

SP - 665

EP - 668

JO - Otology and Neurotology

JF - Otology and Neurotology

SN - 1531-7129

IS - 5

ER -